Activities of AVA LifeScience
Our explicit goal for the future is the development of specific mABs against autoimmune diseases, e.g. Multiple Sclerosis or Rheumatoid Arthritis.
The first product of the AVA-NextGenMonoclonals™ platform is AVA-mAb01™, which opens up a completely new world for targeted therapies with its exceptional tumor specificity.
AVA-mAb01™ is directed against a specific surface structure present on malignant B-cells of an aggressive chronic lymphocytic leukemia (CLL) form. Due to its high accuracy, AVA-mAb01™ allows not only stratified pharmacotherapy but also the establishment of an innovative companion diagnostics.